New Zealand Approves MDMA for PTSD Treatment

Two psychiatrists in New Zealand received official approval on Friday to prescribe pharmaceutical‑grade MDMA to patients suffering from severe post‑traumatic stress disorder (PTSD). The decision, made by the Ministry of Health’s Medicines and Medical Devices Safety Authority, follows a series of clinical trials that demonstrated the drug’s effectiveness when administered in a controlled therapeutic setting.

The psychiatrists, who have been involved in research on psychedelic‑assisted therapy, will be able to offer MDMA‑assisted psychotherapy to a limited number of patients under strict supervision. The approval is part of a broader move to expand access to evidence‑based treatments for PTSD, a condition that affects an estimated 1 in 10 New Zealanders. The Ministry indicated that the prescription program will be closely monitored, with data collected to assess safety and efficacy before any wider rollout.

The new prescription authority marks a significant step in the country’s mental‑health policy, aligning New Zealand with other jurisdictions that have begun to legalise MDMA‑assisted therapy for treatment‑resistant PTSD. The psychiatrists and their teams will now begin to enrol patients, with the aim of providing an alternative option for those who have not responded to conventional medication or psychotherapy.